SUO 2016: Novel predictive biomarkers for benefit of chemotherapy focusing on ERCC2 and other platinum sensitivity biomarkers - Session Highlights

San Antonio, Texas USA ( Gopa Iyer, Memorial Sloan Kettering Cancer Center, discussed biomarkers for benefit of chemotherapy treated patients. Genetic sequencing of outliers to identify predictors of platinum sensitivity or resistance were able to discern ERCC2 mutations noted in responders versus non-responders.

Genetic alteration signature were also important for predicting response to chemotherapy. Deleterious DNA damage response gene alterations have been noted to predict response to neoadjuvant chemotherapy with variations in ERCC2 noted with response. Molecular subtyping based on RNA expression signatures with p-53 like subtypes more likely to be chemotherapy resistant which have been shown in MVAC phase II trials and ddMVAC phase II samples. COXEN is a system used for gene expression models to be used for the development of a COXEN score for responders v non-responders to chemotherapy. S1314 is a randomized phase II study underway to asses COXEN in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer. Future directions include contribution of DNA and RNA signatures in addition to exploring these biomarkers in the adjuvant and metastatic setting.

Presented By: Gopa Iyer, Memorial Sloan Kettering Cancer Center

Written By: Stephen B. Williams, MD and Ashish M. Kamat

17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA